Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer

AI-306Positive

AI Analysis

Summary

Apeximmune's novel immune checkpoint target PLA2G2D has been validated by two independent research teams and published in Nature, demonstrating potential to overcome anti-PD-1 resistance in cancer. The company's first-in-class anti-PLA2G2D antibody AI-306 is advancing toward IND filing in Q2 2027.

Outcome Details

Novel immune checkpoint PLA2G2D validated by independent research teams; first-in-class anti-PLA2G2D antibody advancing toward IND filing

Importance:7/10

Sentiment:

0.85

immunotherapycheckpoint inhibitorcancerPD-1 resistanceantibodytarget validationNature publication

Related Companies

$CKPT $CBDY $TRAX

Read the original article

Published by PR Newswire Biotech on September 9, 2026 3:02 PM

Read Original